Global Cancer Biomarkers Market Opportunity Analysis and Industry Forecast till 2031: By Biomarker Type (Protein Biomarker, Genetic Biomarker, Others), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), By Profiling Technologies (Omics Technology, Imaging Technologies, Immunoassays, Bioinformatics, Cytogenetics), By Application (Diagnostics, Research & Development, Prognostics, Risk Assessments, Others); and By Region
The global cancer biomarkers market size was USD 13.4 billion in 2021 and it is anticipated to reach USD 63.6 billion by 2031, growing at a CAGR of 16.9% from 2022-2031.
Cancer biomarkers are substances or processes that indicate the presence of cancers in the human body, estimated by collecting samples such as stool, tumor tissue, blood, urine, or other tissues or bodily fluids. Biomarkers may be formed by the cancer tissue itself or by other cells in the body in response to cancer. They enhance cancer detection and assist in high-speed noninvasive diagnosis using genomics and proteomics.
Global Cancer Biomarkers Market Scope and Structure AnalysisMarket Trends and Drivers
The key factor boosting the growth of the market is rising technological advancements in the development of cancer biomarkers. The advancements in arrays and proteomics technologies have addressed the challenges in identifying and understanding the functions and interactions of various proteins. These technological advancements have simplified the process of discovery & development of novel cancer biomarkers to great extent.
Similarly, the growing preference for personalized medicine is also boosting the growth of the market. Personalized medicine identifies the most beneficial treatment path for individual patients. Cancer biomarkers play a very important role in certain aspects of personalized medicine. Consumables used in cancer biomarker testing enable the identification of these diseases. Cancer biomarker diagnostic products are also used as companion diagnostics for several investigational therapies. So, the field of personalized medicine is likely to offer potential growth opportunities for players operating in the cancer biomarkers market.
Market Restraints and Challenges
The key factor hampering the growth of the global cancer biomarker market is technical issues related to sample collection and storage. The sample collection is one of the key issues for service providers, followed by access to these samples. Stringent quality control of this sample is essential, and they need to be stored under the right conditions to avoid any loss. Additionally, different samples are required for risk detection, screening, diagnosis, and monitoring processes. Likewise, challenges associated with cancer biomarker validation is also hindering the growth of the market. The cancer biomarker validation process comprises evaluation assays or measuring performance characteristics like sensitivity, specificity, and reproducibility. Validation is critical for establishing cancer biomarkers as reliable tool to support development, medical care, and biopharma investment decisions.
Global Cancer Biomarkers Market Segmentation
The report analyses the global cancer biomarkers market based on biomarker type, cancer type, profiling technologies, application, and region.
Global Cancer Biomarkers Market by Biomarker Type
Based on biomarker type, it is segmented into protein biomarkers, genetic biomarkers, and others. The protein biomarker segment is likely to dominate the market during the forecast period. The key factors such as increasing research on cancer biomarkers are propelling the growth of the market.
Global Cancer Biomarkers Market by Cancer Type
Based on cancer type, it is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others. The breast cancer segment is anticipated to dominate the market during the forecast period. The key factors such as the increasing incidence of cancer across the globe are boosting the growth of the market.
Global Cancer Biomarkers Market by Profiling Technologies
Based on profiling technologies, it is segmented into omics technologies, imaging technologies, immunoassays, bioinformatics, and cytogenetics. The omics technologies are estimated to dominate the market during the forecast period. The key factors such as the increased use of cancer biomarkers for new developments are boosting the growth of this segment.
Global Cancer Biomarkers Market by Application
Based on application, it is segmented into, it is segmented into diagnostics, research & development, prognostics, risk assessments, and others. The diagnostic segment is likely to dominate the market during the forecast period. The factors such as an increase in the application of cancer biomarkers for companion diagnostics will boost the market growth during the forecast period.
Geographical Analysis of Global Cancer Biomarkers Market
Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the global cancer biomarkers market. The North American cancer biomarkers market’s growth can be attributed to the correlation between the rising population and increased research activities.
Major Players in Global Cancer Biomarkers Market
The major key players in the cancer biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).
COVID-19 Analysis
It was primarily thought novel coronavirus (covid-19, sars-cov-2) was majorly a respiratory disorder, but as larger numbers of patients contracted the virus, it rapidly became clear it had many physiological manifestations. The impact of covid-19 goes well beyond the lungs to impact the cardiovascular system and cause complications in the kidneys, brain, and other organs. Critical patients frequently require care from a multidisciplinary care team. Moreover, COVID patients with comorbidities were more likely to have severe symptoms requiring hospitalization. Yet, patients with pre-existing cardiovascular diseases suffer the highest mortality rate of all COVID patients.
The implications of decreased testing are of great concern for many stakeholders, comprising physicians, hospitals, laboratories, pharmaceutical companies, and, most probably, patients. Diagnosis and cancer biomarker testing is the earliest indicators of treatment, which may comprise new targeted therapies with the potential to improve patient results; they should not be delayed. Routine screening for breast, ovarian and colorectal cancer also needs to be done timely as they constitute effective preventive and early detection measures. The pandemic has significantly and negatively altered how cancer patients are being diagnosed and treated in the upcoming years.
Recent Developments
- February 2022, Onco DNA introduced the Onco Deep Solid Tumor Biomarker Test Kit. The Onco Deep kit, which comprises Twist Bioscience’s enrichment and library preparation solutions, will give labs a complete and reliable solution for performing comprehensive NGS analysis of tumor samples.
- April 2021, F. Hoffmann-La Roche Ltd., launched Elecsys Anti-p53 immunoassay to assist in the diagnosis of various cancer types.
- December 2020, Thermo Fisher Scientific (US) received FDA approval for NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
- April 2020, Qiagen N.V. launched the therascreen BRAF test as a companion diagnostic to a BRAFTOVI-based regimen in metastatic colorectal cancer.
- May 2019, Biotech Support Group (BSG) and Leiden University Medical Center (LUMC) have established a research partnership to identify stromal conditioning biomarkers in Cancer.
Q. How big is the cancer biomarkers market?Ans. The global cancer biomarkers market size was USD 13.4 Million in 2021 and is anticipated to reach USD 63.6 Million in 2031, growing at a rate of 16.9% from 2022 to 2031.
Q. What is the cancer biomarkers market growth rate?Ans. The growth rate of the cancer biomarkers market is 16.9% from 2022 to 2031.
Q. Which Ans. North America holds a major market share of the cancer biomarkers market in 2021.
Q. Which segment accounted for the largest cancer biomarkers market share?Ans. By application, the diagnostic segment accounted for the largest cancer biomarkers market share
Q. Who are the key players in the breath analyzer market?Ans. The global cancer biomarkers market report includes players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).
Q. What are the factors driving the cancer biomarkers market growth?Ans. The major factors driving the growth of the market are the increasing incidences of cancer.
Q. What are the key growth strategies of cancer biomarkers market players?Ans. The key growth strategies of cancer biomarkers market players are product launch and product approval.
Q. Which Ans. The Asia-Pacific region will provide more business opportunities for cancer biomarkers market during the forecast period.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
- Chapter 1. MARKET INTRODUCTION
- 1.1. OBJECTIVES OF THE STUDY
- 1.2. MARKET DEFINITION AND RESEARCH & SCOPE
- 1.3. RESEARCH METHODOLOGIES
- 1.4. MARKET ESTIMATION TECHNIQUES
- Chapter 2. EXECUTIVE SUMMARY
- 2.1. SUMMARY
- 2.2. KEY HIGHLIGHTS OF THE MARKET
- Chapter 3. CANCER BIOMARKER MARKET OUTLOOK
- 3.1. CANCER BIOMARKER MARKET SEGMENTATION
- 3.2. MARKET DYNAMICS
- 3.2.1. MARKET DRIVERS
- 3.2.1.1. DRIVER 1
- 3.2.1.2. DRIVER 2
- 3.2.1.3. DRIVER 3
- 3.2.2. MARKET RESTRAINTS
- 3.2.2.1. RESTRAINT 1
- 3.2.2.2. RESTRAINT 2
- 3.2.3. MARKET OPPORTUNITIES
- 3.2.3.1. OPPORTUNITY 1
- 3.2.3.2. OPPORTUNITY 2
- 3.3. PORTER’S FIVE FORCES ANALYSIS
- 3.3.1. THREAT OF NEW ENTRANTS
- 3.3.2. THREAT OF SUBSTITUTES
- 3.3.3. BARGAINING POWER OF BUYERS
- 3.3.4. BARGAINING POWER OF SUPPLIER
- 3.3.5. COMPETITIVE RIVALRY
- 3.4. PESTLE ANALYSIS
- 3.5. VALUE CHAIN ANALYSIS
- 3.5.1. RAW MATERIAL SUPPLIERS
- 3.5.2. MANUFACTURERS
- 3.5.3. WHOLESALERS AND/OR RETAILERS
- 3.6. IMPACT OF THE RUSSIA AND UKRAINE WAR ON THE GLOBAL CANCER BIOMARKER MARKET
- Chapter 4. ECONOMIC IMPACT OF COVID-19
- 4.1. OVERALL IMPACT OF COVID-19
- 4.2. IMPACT OF COVID ON THE GLOBAL CANCER BIOMARKER MARKET
- 4.3. ECONOMIC IMPACT ANALYSIS
- Chapter 5. CANCER BIOMARKER MARKET BY BIOMARKER TYPE
- 5.1. MARKET OVERVIEW
- 5.2. PROTEIN BIOMARKER
- 5.2.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 5.2.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 5.3. GENETICS BIOMARKERS
- 5.3.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 5.3.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 5.4. OTHERS
- 5.4.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 5.4.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- Chapter 6. CANCER BIOMARKER MARKET BY CANCER TYPE
- 6.1. MARKET OVERVIEW
- 6.2. BREAST CANCER
- 6.2.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 6.2.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 6.3. LUNG CANCER
- 6.3.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 6.3.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 6.4. COLORECTAL CANCER
- 6.4.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 6.4.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 6.5. PROSTATE CANCER
- 6.5.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 6.5.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 6.6. MELANOMA
- 6.6.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 6.6.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 6.7. OTHERS
- 6.7.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 6.7.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- Chapter 7. CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGIES
- 7.1. MARKET OVERVIEW
- 7.2. OMICS BIOMARKER TYPE
- 7.2.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 7.2.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 7.3. IMAGING BIOMARKER TYPE
- 7.3.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 7.3.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 7.4. IMMUNOASSAY
- 7.4.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 7.4.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 7.5. BIOINFORMATICS
- 7.5.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 7.5.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 7.6. CYTOGENETICS
- 7.6.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 7.6.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- Chapter 8. CANCER BIOMARKERS MARKET BY APPLICATION
- 8.1. MARKET OVERVIEW
- 8.2. DIAGNOSTICS
- 8.2.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 8.2.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 8.3. RESEARCH AND DEVELOPMENTS
- 8.3.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 8.3.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 8.4. PROGNOSTICS
- 8.4.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 8.4.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 8.5. RISK ASSESSMENTS
- 8.5.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 8.5.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- 8.6. OTHERS
- 8.6.1. MARKET SIZE AND FORECAST, 2021-2031 ($MILLION)
- 8.6.2. MARKET SIZE AND FORECAST, BY REGION, 2021-2031 ($MILLION)
- Chapter 9. CANCER BIOMARKER MARKET, BY REGION
- 9.1. OVERVIEW
- 9.2. NORTH AMERICA
- 9.2.1. KEY MARKET TRENDS AND OPPORTUNITIES
- 9.2.2. NORTH AMERICA CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.2.3. NORTH AMERICA CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.2.4. NORTH AMERICA CANCER BIOMARKER MARKET SIZE AND FORECAST BY COUNTRY, 2021-2031, ($MILLION)
- 9.2.5. THE U.S.
- 9.2.5.1. THE U.S. CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.2.5.2. THE U.S. CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.2.6. CANADA
- 9.2.6.1. CANADA CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.2.6.2. CANADA CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.2.7. MEXICO
- 9.2.7.1. MEXICO CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.2.7.2. MEXICO CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3. EUROPE
- 9.3.1. KEY MARKET TRENDS AND OPPORTUNITIES
- 9.3.2. EUROPE CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3.3. EUROPE CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.3.4. EUROPE CANCER BIOMARKER MARKET SIZE AND FORECAST BY COUNTRY, 2021-2031, ($MILLION)
- 9.3.5. GERMANY
- 9.3.5.1. GERMANY CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3.5.2. GERMANY CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.3.6. FRANCE
- 9.3.6.1. FRANCE CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3.6.2. FRANCE CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.3.7. U.K.
- 9.3.7.1. U.K. CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3.7.2. U.K. CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.3.8. SPAIN
- 9.3.8.1. SPAIN CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3.8.2. SPAIN CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.3.9. ITALY
- 9.3.9.1. ITALY CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3.9.2. ITALY CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.3.10. RUSSIA
- 9.3.10.1. RUSSIA CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3.10.2. RUSSIA CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.3.11. REST OF EUROPE
- 9.3.11.1. REST OF EUROPE CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.3.11.2. REST OF EUROPE CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.4. ASIA-PACIFIC
- 9.4.1. KEY MARKET TRENDS AND OPPORTUNITIES
- 9.4.2. ASIA-PACIFIC CANCER BIOMARKER MARKET SIZE AND FORECAST BY COUNTRY, 2021-2031, ($MILLION)
- 9.4.3. ASIA-PACIFIC CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.4.4. ASIA-PACIFIC CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.4.5. CHINA
- 9.4.5.1. CHINA CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.4.5.2. CHINA CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.4.6. INDIA
- 9.4.6.1. INDIA CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.4.6.2. INDIA CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.4.7. JAPAN
- 9.4.7.1. JAPAN CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.4.7.2. JAPAN CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.4.8. SOUTH KOREA
- 9.4.8.1. SOUTH KOREA CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.4.8.2. SOUTH KOREA CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.4.9. REST OF APAC
- 9.4.9.1. REST OF APAC CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.4.9.2. REST OF APAC CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.5. REST OF THE WORLD
- 9.5.1. KEY MARKET TRENDS AND OPPORTUNITIES
- 9.5.2. REST OF THE WORLD CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.5.3. REST OF THE WORLD CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.5.4. REST OF THE WORLD CANCER BIOMARKER MARKET SIZE AND FORECAST BY COUNTRY, 2021-2031, ($MILLION)
- 9.5.5. LATIN AMERICA
- 9.5.5.1. LATIN AMERICA CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.5.5.2. LATIN AMERICA CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.5.6. MIDDLE EAST
- 9.5.6.1. MIDDLE EAST CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.5.6.2. MIDDLE EAST CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- 9.5.7. AFRICA
- 9.5.7.1. AFRICA CANCER BIOMARKER MARKET SIZE AND FORECAST BY BIOMARKER TYPE, 2021-2031, ($MILLION)
- 9.5.7.2. AFRICA CANCER BIOMARKER MARKET SIZE AND FORECAST BY APPLICATION, 2021-2031, ($MILLION)
- Chapter 10. COMPETITIVE LANDSCAPE
- 10.1. MARKET OVERVIEW
- 10.2. MARKET SHARE ANALYSIS/KEY PLAYER POSITIONING
- 10.3. DEVELOPMENTAL STRATEGY BENCHMARKING
- 10.3.1. NEW APPLICATION DEVELOPMENT
- 10.3.2. BIOMARKER TYPE LAUNCHES
- 10.3.3. BUSINESS EXPANSIONS
- 10.3.4. PARTNERSHIPS, JOINT VENTURES, AND COLLABORATIONS
- 10.3.5. MERGERS AND ACQUISITIONS
- Chapter 11. COMPANY PROFILES
- 11.1. F. Hoffmann-La Roche Ltd. (Switzerland)
- 11.1.1. COMPANY SNAPSHOT
- 11.1.2. FINANCIAL PERFORMANCE
- 11.1.3. BIOMARKER TYPE OFFERINGS
- 11.1.4. KEY STRATEGIC INITIATIVES
- 11.1.5. SWOT ANALYSIS
- 11.2. Thermo Fisher Scientific, Inc. (US)
- 11.2.1. COMPANY SNAPSHOT
- 11.2.2. FINANCIAL PERFORMANCE
- 11.2.3. BIOMARKER TYPE OFFERINGS
- 11.2.4. KEY STRATEGIC INITIATIVES
- 11.2.5. SWOT ANALYSIS
- 11.3. QIAGEN N.V. (Netherlands)
- 11.3.1. COMPANY SNAPSHOT
- 11.3.2. FINANCIAL PERFORMANCE
- 11.3.3. BIOMARKER TYPE OFFERINGS
- 11.3.4. KEY STRATEGIC INITIATIVES
- 11.3.5. SWOT ANALYSIS
- 11.4. Illumina, Inc. (US)
- 11.4.1. COMPANY SNAPSHOT
- 11.4.2. FINANCIAL PERFORMANCE
- 11.4.3. BIOMARKER TYPE OFFERINGS
- 11.4.4. KEY STRATEGIC INITIATIVES
- 11.4.5. SWOT ANALYSIS
- 11.5. Bio-Rad Laboratories, Inc. (US)
- 11.5.1. COMPANY SNAPSHOT
- 11.5.2. FINANCIAL PERFORMANCE
- 11.5.3. BIOMARKER TYPE OFFERINGS
- 11.5.4. KEY STRATEGIC INITIATIVES
- 11.5.5. SWOT ANALYSIS
- 11.6. Abbott Laboratories (US)
- 11.6.1. COMPANY SNAPSHOT
- 11.6.2. FINANCIAL PERFORMANCE
- 11.6.3. BIOMARKER TYPE OFFERINGS
- 11.6.4. KEY STRATEGIC INITIATIVES
- 11.6.5. SWOT ANALYSIS
- 11.7. bioMérieux SA (US)
- 11.7.1. COMPANY SNAPSHOT
- 11.7.2. FINANCIAL PERFORMANCE
- 11.7.3. BIOMARKER TYPE OFFERINGS
- 11.7.4. KEY STRATEGIC INITIATIVES
- 11.7.5. SWOT ANALYSIS
- 11.8. Becton, Dickinson and Company (US)
- 11.8.1. COMPANY SNAPSHOT
- 11.8.2. FINANCIAL PERFORMANCE
- 11.8.3. BIOMARKER TYPE OFFERINGS
- 11.8.4. KEY STRATEGIC INITIATIVES
- 11.8.5. SWOT ANALYSIS
- 11.9. Merck Millipore (US)
- 11.9.1. COMPANY SNAPSHOT
- 11.9.2. FINANCIAL PERFORMANCE
- 11.9.3. BIOMARKER TYPE OFFERINGS
- 11.9.4. KEY STRATEGIC INITIATIVES
- 11.9.5. SWOT ANALYSIS
- 11.10. Agilent Technologies (US)
- 11.10.1. COMPANY SNAPSHOT
- 11.10.2. FINANCIAL PERFORMANCE
- 11.10.3. BIOMARKER TYPE OFFERINGS
- 11.10.4. KEY STRATEGIC INITIATIVES
- 11.10.5. SWOT ANALYSIS
- 11.11. Myriad Genetics, Inc. (US)
- 11.11.1. COMPANY SNAPSHOT
- 11.11.2. FINANCIAL PERFORMANCE
- 11.11.3. BIOMARKER TYPE OFFERINGS
- 11.11.4. KEY STRATEGIC INITIATIVES
- 11.11.5. SWOT ANALYSIS
- *The list of company is subject to change during the final compilation of the report
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook